Drill-free treatment for early-stage tooth decay · Zug, Switzerland
Pinch-zoom for details.
Use of proceeds, per the filing: general corporate purposes (working capital, operating expenses, capital expenditures), and possibly acquisitions. No dividends planned.
vVARDIS sells Curodont, a peptide-based liquid applied to early-stage cavities. The company says it helps stop the decay and rebuild enamel without drilling, in a treatment of up to five minutes.
Fiscal year
First half (Jan–Jun)
Net loss, fiscal year
Net loss, first half
Selling, general & administrative costs were $59.9M in FY2025, about twice revenue. Interest expense was $11.8M. Cash used in operations: $16.3M in H1 2026.
Share of FY2025 net revenue ($30.2M). U.S. $28.7M; Switzerland, Italy, U.K. and others $1.5M. The filing doesn't name the customers.
June 30, 2026, actual vs. "pro forma as adjusted" for the offering at the $22.50 midpoint, as shown in the filing. Total shareholders' equity goes from −$118.5M to $138.0M on the same basis.
Co-founders and co-CEOs Haley and Goly Abivardi hold all Class B voting shares. Each Class B share has a tenth of the par value of a Class A share but the same one vote.
Founders' share after the offering, without the over-allotment option. Other holders above 5% economic after the IPO: Curo Bidco 8.8%, Heartland Dental 7.0%, Cerebro Equity 5.1%. The company will be a "controlled company" under NYSE rules.
| $000s | H1 2026 | H1 2025 | H/H | FY2025 | FY2024 | YoY |
|---|---|---|---|---|---|---|
| Net revenue | 28,558 | 9,088 | +214.2% | 30,209 | 12,157 | +148.5% |
| Cost of goods sold | (3,885) | (4,417) | −12.0% | (7,792) | (8,269) | −5.8% |
| R&D | (7,159) | (2,002) | +257.6% | (4,575) | (2,641) | +73.2% |
| SG&A | (35,064) | (26,750) | +31.1% | (59,925) | (32,213) | +86.0% |
| Loss from operations | (17,550) | (24,081) | −27.1% | (42,084) | (30,966) | +35.9% |
| Interest expense | (9,015) | (4,061) | +122.0% | (11,753) | (3,942) | +198.1% |
| Net loss | (27,807) | (32,057) | −13.3% | (56,447) | (34,737) | +62.5% |
| Operating cash flow | (16,317) | (22,755) | −28.3% | (16,333) | (23,797) | −31.4% |
| First half, $000s | H1 2026 | H1 2025 | H/H |
|---|---|---|---|
| Net revenue | 28,558 | 9,088 | +214.2% |
| Cost of goods sold | (3,885) | (4,417) | −12.0% |
| R&D | (7,159) | (2,002) | +257.6% |
| SG&A | (35,064) | (26,750) | +31.1% |
| Loss from operations | (17,550) | (24,081) | −27.1% |
| Interest expense | (9,015) | (4,061) | +122.0% |
| Net loss | (27,807) | (32,057) | −13.3% |
| Operating cash flow | (16,317) | (22,755) | −28.3% |
| Fiscal year, $000s | FY2025 | FY2024 | YoY |
|---|---|---|---|
| Net revenue | 30,209 | 12,157 | +148.5% |
| Cost of goods sold | (7,792) | (8,269) | −5.8% |
| R&D | (4,575) | (2,641) | +73.2% |
| SG&A | (59,925) | (32,213) | +86.0% |
| Loss from operations | (42,084) | (30,966) | +35.9% |
| Interest expense | (11,753) | (3,942) | +198.1% |
| Net loss | (56,447) | (34,737) | +62.5% |
| Operating cash flow | (16,333) | (23,797) | −31.4% |
H/H: first half 2026 vs first half 2025. YoY: fiscal 2025 vs fiscal 2024. Both are the change in the size of each line, worked out from the filed figures; green means better for the company (more revenue, lower costs or losses), red means worse. FY2024 and FY2025 audited; half-years unaudited. Gross margins for FY2024 (32.0%) and H1 2025 (51.4%) in the charts are worked out from these lines.
In plain English, from the filing's risk factors.
In plain English, from the filing's growth strategies.
Source: every figure is from vVARDIS's Form F-1/A, Amendment No. 2, filed with the SEC on November 12, 2026 (preliminary prospectus). The final price will be in the 424B4 prospectus. Not investment advice.
Pinch-zoom for details.
10KDecoder (10-K Decoder): decode SEC 10-K filings and IPO prospectuses into dashboards and infographics.
Infographic
Double-tap: full screen or back